Skip to main content

Table 4 Univariate and multivariate analyses of variables associated with pCR

From: Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models

Variable

Univariate analysis

Multivariate analysis

Odds ratio*

P value

Odds ratio*

P value

Pre-treatment

 Age

0.986 (0.953, 1.021)

0.429

–

–

 Menopause (post- vs. pre-menopausal)

2.083 (0.895, 4.850)

0.089

–

–

 Histologic type (IDC vs. Non-IDC)

1.770 (0.177, 17.665)

0.626

–

–

 ER (negative vs. positive)

11.388 (4.367, 29.698)

< 0.001

11.433 (3.363, 38.874)

< 0.001

 PR (negative vs. positive)

2.388 (0.970, 5.881)

0.058

–

–

 HER2 (positive vs. negative)

5.104 (2.131, 12.227)

< 0.001

5.469 (1.631, 18.339)

0.006

 Ki-67 (≥ 20% vs. < 20%)

14.087 (1.795, 110.566)

0.012

3.852 (0.299, 49.574)

0.301

Mid-treatment

 ΔADC200,1000 (> 0.33 vs. ≤ 0.33 × 10–3 mm2/s)

13.481 (5.066, 35.877)

< 0.001

9.074 (2.847, 28.917)

< 0.001

 ΔSize (≤ − 26.6 vs. > − 26.6 mm)

5.098 (2.070, 12.553)

< 0.001

2.351 (0.697, 7.931)

0.168

 ΔRER (≤ − 87.5% vs. > -87.5%)

4.202 (1.748, 10.100)

0.001

1.231 (0.339, 4.467)

0.752

  1. *Data in parentheses are 95% confidence intervals
  2. For binary categorical variables, the latter category in the parentheses was used as the reference
  3. IDC: invasive ductal carcinoma; pCR: pathologic complete response; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; ADC: apparent diffusion coefficient; RER: relative enhancement ratio